A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease [10]

Leukemia

Volumn 21, Issue 8, 2007, Pages 1839-1841

  Curtis, C E ^a   Grand, F H ^a   Waghorn, K ^a   Sahoo, T P ^b   George, J ^b   Cross, N C P ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD11 ANTIGEN; CD15 ANTIGEN; CD45 ANTIGEN; GLYCOPROTEIN P 15095; HYBRID PROTEIN; IMATINIB; INTERLEUKIN 3; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR TRANSCRIPTION FACTOR ETV6 FUSION PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ASPIRATION BIOPSY; ATYPICAL CHRONIC MYELOID LEUKEMIA; BONE MARROW BIOPSY; BONE SWELLING; CHROMOSOME 12; CHROMOSOME 5; CHROMOSOME TRANSLOCATION; CHROMOSOME VARIANT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ERROR; FLOW CYTOMETRY; GENE FUSION; HEPATOSPLENOMEGALY; HUMAN; LETTER; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 34447629348     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404728     Document Type: Letter

References (8)

1. Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107: 113-122.
2. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002; 99: 1776-1784.
3. Tokita K, Maki K, Tadokoro J, Nakamura Y, Aral Y, Sasaki K et al. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia 2007; 21: 190-192.
4. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20: 827-832.
5. Kreil S, Pfirrmann M, Hareflach C, Waghim K, Chase A, Hehlamnn R et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007, E-pub April 24.
6. Cools J, DeAngelo, DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
7. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006; 103: 8078-8083.
8. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, E-pub March 22.